LPAR3 and cancer: Among them, Y7g exhibited selective antagonistic activities against vasopressin receptor 2 and oxytocin receptor suggesting that targeting GPCR by small molecules can lead to the identification of new compounds capable of interacting with distinct cancer-relevant targets.